Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Part D Coverage For Humira Biosimilars Has Inspector General’s Attention

Executive Summary

Office of Inspector General analysis could add momentum to reforms of the rebating system.

You may also be interested in...



Medicare Price Negotiation Law Fixes Face ‘Big Problem,’ Former Trump Official Says

Health policy experts and biopharma supply chain stakeholders discuss prospects for legislation reforming the Inflation Reduction Act, pharmacy benefit manager practices, and the 340B program during a recent conference.

Humira Horsepower: AbbVie’s Brand Retains 98% US Market Share

Amgen’s Amjevita, the first biosimilar of Humira to launch in the US, hasn’t made headway into the US market, according to Samsung Bioepis’ quarterly market report on the US biosimilars market.

The Immortal Humira? In Huge Test For US Biosimilar Policy, Brand May Still Have Edge

First Humira biosimilar launches raise worries about holes in US health system that may let the brand product continue to dominate. If Humira biosimilars can’t get a strong foothold, reform to biosimilar policy for medicines reimbursed through the pharmacy benefit may be necessary if the US wants to rely on these products to bring down the cost of brand biologics.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153131

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel